Cerebral Cortex Advance Access first published online on July 21, 2004
This version published online on December 8, 2004
Cerebral Cortex, doi:10.1093/cercor/bhh127
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 INSERM E 9935 & Service de Neuropédiatrie, Hôpital Robert-Debré, F-75019 Paris, France
* To whom correspondence should be addressed. Excitotoxicity may be critical in the formation of brain lesions associated with cerebral palsy. When injected into the murine neopallium at postnatal day (P) 5, ibotenate (activating NMDA and metabotropic glutamate receptors) produces neuronal death and white matter cysts. Such white matter cysts resemble those seen in periventricular leukomalacia, a lesion evident in numerous human premature newborns. The goal of this study was to assess BDNF neuroprotection against neonatal excitotoxic lesions. Cortical and white matter lesions induced by ibotenate at P5 were reduced by BDNF by up to 36 and 60%, respectively. BDNF neuroprotection involved TrkB receptors, MAPK pathway and reduced apoptosis. Although BDNF did not prevent the initial appearance of white matter lesions, it promoted secondary decrease of the lesion size. BDNF neuroprotection at P5 was maximal against lesions induced by NMDA or ibotenate but was moderate against lesions produced by an AMPA-kainate agonist. Finally, BDNF exacerbated neuronal death produced by ibotenate at P0 through increased apoptosis and p75NTR receptors, while BDNF had no detectable effect on lesions induced at P10. Altogether, these data showed that BDNF neuroprotection against neonatal excitotoxicity is dependent upon the type of activated glutamate receptors, the lesion localization and the developmental stage.
Article
BDNF-induced White Matter Neuroprotection and Stage-dependent Neuronal Survival Following a Neonatal Excitotoxic Challenge
2 INSERM E 9935 & Service de Neuropédiatrie, Hôpital Robert-Debré, F-75019 Paris, France; Mental Retardation Research Center, University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA 90095, USA
3 CNRS UMR 7091, Bâtiment CERVI, Hôpital de la Pitié-Salpétrière, F-75013 Paris, France
4 INSERM E 9935 & Service de Neuropédiatrie, Hôpital Robert-Debré, F-75019 Paris, France; Laboratory of Molecular & Developmental Neuroscience, Boston, MA 02129, USA
Pierre Gressens, E-mail: gressens{at}rdebre.inserm.fr
Abstract
Figure 8A has been corrected.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Degos, G. Loron, J. Mantz, and P. Gressens Neuroprotective Strategies for the Neonatal Brain Anesth. Analg., June 1, 2008; 106(6): 1670 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-M. Rangon, S. Fortes, V. Lelievre, P. Leroux, F. Plaisant, C. Joubert, L. Lanfumey, C. Cohen-Salmon, and P. Gressens Chronic Mild Stress during Gestation Worsens Neonatal Brain Lesions in Mice J. Neurosci., July 11, 2007; 27(28): 7532 - 7540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Medja, V. Lelievre, R. H. Fontaine, F. Lebas, P. Leroux, T. Ouimet, A. Saria, C. Rougeot, P. Dournaud, and P. Gressens Thiorphan, a neutral endopeptidase inhibitor used for diarrhoea, is neuroprotective in newborn mice Brain, December 1, 2006; 129(12): 3209 - 3223. [Abstract] [Full Text] [PDF]
|
|